Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Statins, Rise Of The Subgroups? IMPROVE-IT Suggests Population Choice Key

Executive Summary

Diabetics seem to have benefited from Zetia, but not rest of high-risk patients in IMPROVE-IT – suggesting next-step cholesterol drugs might wind up being targeted to subgroups.

Advertisement

Related Content

IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
Merck’s Zontivity Label Isn’t Weighed Down With Safety Language
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel